NASDAQ
Metsera Inc. (NASDAQ: MTSR - Get Free Report) has been given a consensus rating of "Hold" by the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating...
Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bi...
Metsera was the target of a bidding war by pharma giants. The company has an innovative obesity drug candidate....
On this episode of Stock Movers with Lisa Mateo: - Metsera (MTSR) shares tank in premarket trading after Novo Nordisk A/S declined to further raise its offer for the US maker of an experimental weight...
Metsera (NASDAQ:MTSR) announced that it has entered into an amended merger agreement with Pfizer Inc (NYSE:PFE, ETR:PFE), under which Pfizer will acquire the biotech company for up to $86.25 per share...
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted ...
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical de...
Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could bring an end to the shutdown that has lasted nearly six weeks; President D...
The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments....
No price data available for this timeframe.